Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (avab uue akna)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Allikas‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indekseeritud‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (avab uue akna)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (avab uue akna)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Allikas‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indekseeritud‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (avab uue akna)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (avab uue akna)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Allikas‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indekseeritud‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (avab uue akna)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (avab uue akna)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Allikas‎: Blood 2003;102(4):1529-30.

Indekseeritud‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (avab uue akna)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (avab uue akna)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Allikas‎: Transfusion 2007;47(10):1830-6.

Indekseeritud‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (avab uue akna)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (avab uue akna)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Allikas‎: Iran J Blood Cancer 2009;1(4):147-50.

Indekseeritud‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (avab uue akna)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (avab uue akna)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Allikas‎: Int J Hematol 2012;95(1):51-6.

Indekseeritud‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (avab uue akna)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (avab uue akna)

Perrine SP.

Allikas‎: Pediatr Ann 2008;37(5):339-46.

Indekseeritud‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (avab uue akna)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (avab uue akna)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Allikas‎: Sci Rep. 2022;12(1):2752.

Indekseeritud‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (avab uue akna)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (avab uue akna)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Allikas‎: Haematologica 2004;89(10):1172-8.

Indekseeritud‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (avab uue akna)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (avab uue akna)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Allikas‎: Arch Iran Med 2009;12(3):295-7.

Indekseeritud‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (avab uue akna)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (avab uue akna)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Allikas‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indekseeritud‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (avab uue akna)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (avab uue akna)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Allikas‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indekseeritud‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (avab uue akna)

Fetal globin gene inducers: novel agents and new potential. (avab uue akna)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Allikas‎: Ann N Y Acad Sci 2010;1202:158-64.

Indekseeritud‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (avab uue akna)